120
Views
97
CrossRef citations to date
0
Altmetric
Article

Ubiquitin-Independent Degradation of Antiapoptotic MCL-1

, , , , &
Pages 3099-3110 | Received 18 Sep 2009, Accepted 02 Apr 2010, Published online: 20 Mar 2023
 

Abstract

Antiapoptotic myeloid cell leukemia 1 (MCL-1) is an essential modulator of survival during the development and maintenance of a variety of cell lineages. Its turnover, believed to be mediated by the ubiquitin-proteasome system, facilitates apoptosis induction in response to cellular stress. To investigate the contribution of ubiquitinylation in regulating murine MCL-1 turnover, we generated an MCL-1 mutant lacking the lysine residues required for ubiquitinylation (MCL-1KR). Here, we demonstrate that despite failing to be ubiquitinylated, the MCL-1KR protein is eliminated at a rate similar to that of wild-type MCL-1 under basal and stressed conditions. Moreover, the degradation of wild-type MCL-1 is not affected when ubiquitin-activating enzyme E1 activity is blocked. Likewise, both wild-type and MCL-1KR proteins are similarly degraded when expressed in primary lymphocytes. Supporting these findings, unmodified, in vitro-translated MCL-1 can be degraded in a cell-free system by the 20S proteasome. Taken together, these data demonstrate that MCL-1 degradation can occur independently of ubiquitinylation.

View publisher note:
Articles of Significant Interest Selected from This Issue by the Editors

We thank S. Oakes, L. Nutt, D. Green, J. Ihle, G. Zambetti, J. Partridge, P. Brindle, and P. Ney for helpful discussions; the St. Jude Transgenic Core Facility for generating the transgenic mice; and J. Roberts, H. Ozer, D. Bohman, K. Helin, M. Pagano, C. Sherr, D. Green, and J. W. Harper for providing reagents.

This work is supported by the American Lebanese Syrian Associated Charities (ALSAC), and the NIH NCI P30CA021765-30. J.T.O. is a Pew Scholar in the Biomedical Sciences.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.